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ABSTRACT (Maximum 200
This work describes the development of a novel system for efficient and rapid introduction of genes into specific tissues or cells in mice. Detailed analysis of gene function often relies upon introduction of genes into an animal model system. We are developing a retroviral-based system in which controlled expression of the cellular receptor for the virus in a defined pattern determines the site(s) of infection. Using this retrovirai gene delivery system, a gene can be introduced not only in a spatial-specific pattern but also in a temporally-controlled manner using a retrovirai vector. For these studies we expressed the receptor for the avian virus Rous sarcoma virus in mammary cells in transgenic mice using a MMTV LTR. The ability to selectively target retrovirai infection has numerous applications in areas as diverse as developmental biology, gene therapy, and oncogenesis. Here we will attempt to utilize this system for targeted expression of genes in mammary cells to rapidly assess the potential of these genes to induce mammary tumors in an animal model.
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BODY AIM 1 Characterization of the MMTV-tva transgenic mice
When this grant was written we had already successfully established two transgenic lines of mice carrying an MMTV-tva transgene. However this past year problems with mouse hepatitis virus (MHV) infection of our transgenic lines that hampered our production of transgenics for these lines. Because of MHV we were required to move these animals to a different ("dirtier") facility, while we prepared to re-derive the lines by embryo transfer.
Unfortunately, at this facility losses due to the MHV infection coupled with poor breeding of our C57BL-6 backcrossed transgenic animals (possibly due to a concurrent pinworm infection) caused both lines #1 and #22 to be lost. Thus, our work this year is to re-establish these mice by re-injecting the same transgene construct into eggs. However, this work is being done at a new strict barrier animal care facility. This facility allows no animals to be imported except by embryo transfer and has experienced no infectious disease outbreaks in its two year existence. Thus we are confident that our transgenic lines will not be We proposed use of a transient system to produce MLV viruses carrying the RSV EnvA protein which would allow directed infection of these viruses into cells expressing tva.
One advantage of this system over replication competent RSV vectors is that the simpler defective MLV vector backbone allows easier insertion of genes and accommodation of larger inserts. In addition, the RSV vector encodes the structural proteins of this virus and when introduced into mice after the neonatal stage is likely to elicit an immune response, potentially resulting in clearance of infected cells carrying the transduced gene. The defective MLV vectors do not encode any structural genes. To fully take advantage of the transient MLV system we needed to extensively modify the original vector described for use in this system (pHIT110). The original vector was quite large (9.1 kb) and contained a G418
resistance gene which we decided to remove to avoid potential immune recognition of infected cells. The plasmid we constructed, pHIT110 poly, is much smaller (5.1kb) and unlike pHIT110, it is derived entirely from known sequences. pHIT110 poly contains a strong cytomengalovirus immediate early enhancer-promoter fused to the R and unique 5' (U5) region of MLV, an extended MLV packaging signal for efficient incorporation of the genomic RNA into virions, a polylinker region with ten unique sites for introducing genes of interest, and the complete 3' MSV LTR for efficient expression of the transduced gene in the infected cells. We have inserted a nuclear localized ß-gal gene into pHIT110 poly and produced MLV(VSV-G) pseudotypes. Using this modified vector titers averaging 1 X 10 6 lU/ml were routinely obtained. Thus the re-engineered MLV vector is functional and will allow construction of marker-or onco-gene encoding viruses.
Another feature required for vectors injected into the mammary gland is high titer.
This requirement stems from the fact that very small volumes can be injected (maximum of 50|il). To achieve the highest titers possible we would like to concentrate the MLV(envA)
viruses. Therefore, we have experimented with two procedures to produce high titer stocks, ultracentrifugation and Ultrafiltration. We find that a high level of concentration can be While the pLNCAP vector will be used in preliminary infection studies optimizing infection parameters (see below), we are currently moving the AP gene into pHIT110 poly to produce pHIT-AP which should avoid immune response problems mentioned above and from our experience should result in higher titer MLV(EnvA) viruses.
AIM 3 in vivo infection of mammary epithelial cells
MLV and RSV infection require nuclear envelope breakdown associated with cellular replication, thus we need to develop protocols in which virus is injected when mammary
Bates, DAMD17-96-1-6242 Annual Report cells are known to be dividing. Unlike most organs, the mammary gland undergoes extensive growth and development after birth in the juvenile and adult animal. Beginning at approximately 3 weeks of age and continuing through 9 weeks, there is extensive proliferation of ductal cells in the mammary gland. These cells also express the MMTV LTR, so this period should allow efficient infection by RSV in the transgenic mice. Another period of mammary cell proliferation occurs during pregnancy in preparation for lactation.
To target cells during this phase of growth, adult (6 month) female mice will be mated, then 14 days after vaginal plugs are noted they will be injected with RSV vectors. The two phases of mammary cell proliferation are not equivalent, so we may target different cells by using these two time frames for infection. Zaire strain glycoprotein (EboGP). Both these envelope proteins mediate infection of a wide variety of cell types in numerous species, thus it is likely that they will allow infection of mammary epithelial cells. We chose to use these envelopes instead of MLV ecotropic envelope (which will also mediate infection of murine cells) because of the stability of VSV-G and EboGP. In both cases viral stocks can be concentrated by centrifugation as described above to produce the titers required for in vivo administration of viruses. This is not the case for the MLV ecotropic envelope protein which is more fragile and does not allow concentration.
MLV(EboGP) and MLV(VSV-G) viruses carrying pMX-GFP or pLNCAP are currently being prepared and concentrated. They will be injected directly into the mammary gland of female mice at the stages of puberty or pregnancy discussed above to determine conditions during which mammary epithelial cells are good targets for retroviral infection in vivo. The optimal conditions determined by these studies will then be employed in future studies with MLV(EnvA) vectors and MMTV-tva mice.
The work completed this year is very preliminary. However, we have determined conditions for producing EnvA carrying viruses at titers that will be useful for in vivo utilization. In addition, we have constructed a CMV promoter-driven MLV vector that will allow construction of marker-or onco-gene expressing vectors for use in vivo. Unlike many available MLV vectors, this vector lacks any other genes that might be immunogenic when injected into adult animals and would therefore complicate analysis of gene transfer into mammary epithelium. Finally, my lab has produced high titer pseudotype viruses carrying broad-tropism envelopes (VSV-G and Ebola GP) that can be used in pilot experiments aimed at defining optimal conditions for infection of mammary epithelial cells.
